5 Stocks Improving Performance Of The Health Care Sector

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.1%) at 15,256 as of Monday, June 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,353 issues advancing vs. 1,578 declining with 107 unchanged.

The Health Care sector currently sits up 0.6% versus the S&P 500, which is up 0.1%. Top gainers within the sector include ACADIA Pharmaceuticals ( ACAD), up 17.1%, UnitedHealth Group ( UNH), up 2.0%, Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.6%, Teva Pharmaceutical Industries ( TEVA), up 1.5% and Aetna ( AET), up 1.2%. On the negative front, top decliners within the sector include Catamaran ( CTRX), down 3.80, Regeneron Pharmaceuticals ( REGN), down 2.09, Smith & Nephew ( SNN), down 1.61, Celgene Corporation ( CELG), down 1.22 and Biogen Idec ( BIIB), down 1.20.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. Edwards Life ( EW) is one of the companies pushing the Health Care sector higher today. As of noon trading, Edwards Life is up $1.96 (2.92) to $69.16 on average volume Thus far, 856,524 shares of Edwards Life exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $68.00-$69.37 after having opened the day at $68.14 as compared to the previous trading day's close of $67.20.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Life has a market cap of $7.5 billion and is part of the health services industry. The company has a P/E ratio of 21.0, above the S&P 500 P/E ratio of 17.7. Shares are down 25.5% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Edwards Life a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Edwards Life Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Edwards Lifesciences: Cramer's Top Takeaways

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Edwards Lifesciences Is Not Skipping A Beat

Canaccord Says Edwards Lifesciences Is Its Favorite Med Tech Stock